Becton, Dickinson and Company $BDX Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC reduced its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 206,911 shares of the medical instruments supplier’s stock after selling 35,818 shares during the period. Great Lakes Advisors LLC owned about 0.08% of Becton, Dickinson and Company worth $31,312,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the third quarter worth $25,000. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at $26,000. Meeder Asset Management Inc. boosted its holdings in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the period. Main Street Group LTD acquired a new position in Becton, Dickinson and Company during the 1st quarter worth $29,000. Finally, Bell Investment Advisors Inc purchased a new stake in Becton, Dickinson and Company during the 2nd quarter worth about $29,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,779 shares of company stock valued at $1,974,669 over the last quarter. Company insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Bank of America reduced their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Finally, Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $185.67.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $181.17 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The stock has a market cap of $49.92 billion, a PE ratio of 54.57, a price-to-earnings-growth ratio of 12.93 and a beta of 0.19. The firm has a fifty day moving average price of $159.06 and a 200 day moving average price of $161.12.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the company posted $3.68 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.